Metoclopramide caused the parkinsonism that levodopa then treated, and levodopa's nausea brought more metoclopramide; this NU553 Unit 7 analysis breaks the loop at its origin. Searches like "nu 553 unit 7 assignment example", "nu553 unit 7 sample" and "nu553 unit 7 example" land here.
What a finished NU553 Unit 7 prescribing cascade analysis looks like
A timeline runs across the top of page one; roughly three further pages hold the analysis. The timeline marks each start, dose change and new symptom by month, with the prescriber beside each. The analysis first establishes plausibility: metoclopramide blocks dopamine D2 receptors, centrally as well as in the gut, and drug-induced parkinsonism is a recognized effect, more likely in older women and with longer use. It cites the 2009 FDA boxed warning on tardive dyskinesia and the advice against use beyond [twelve] weeks. Next it shows the loop: carbidopa-levodopa added dopamine to overcome a blockade the first drug was still producing, levodopa caused nausea, and the nausea was treated with the blocker. The proposal stops metoclopramide first, keeps levodopa unchanged while the parkinsonism is reassessed over [weeks to months], and offers gastroparesis alternatives.
How a NU553 Unit 7 example is structured
Three tests organize the analysis, applied in sequence: timing, pharmacological plausibility, and whether the response to the symptom was a second prescription rather than a review of the first. The timeline settles timing at a glance. Pharmacology settles plausibility, tracing parkinsonism to D2 blockade in the nigrostriatal pathway. The third test is shown through prescriber names, since each clinician acted reasonably on the information in front of them and none saw the whole sequence. The proposal is ordered by pharmacology too: remove the cause, wait for recovery, then reconsider the treatment added for it. Tardive dyskinesia, the reason for the [twelve]-week limit, is noted as a second argument for stopping. Gastroparesis still needs managing, so the plan offers dietary measures and names alternatives with their own limits rather than leaving the original problem untreated.
The months laid out in one line
March, June, August, September: the timeline puts each start and symptom on a single axis with the prescriber named. Seen that way, the tremor's arrival [three] months after the first drug is hard to miss.
A gut drug that reaches the brain
Metoclopramide crosses the blood-brain barrier and blocks D2 receptors in the basal ganglia. That single fact explains tremor, rigidity and slowness, and the analysis cites the 2009 boxed warning for the related risk of tardive dyskinesia.
Levodopa pushing against a blockade
Adding dopamine precursor while the receptor stays blocked produces a partial response at best. The analysis notes that the modest benefit recorded in [August] fits a drug-induced cause better than idiopathic Parkinson disease.
Where the loop closed
Nausea from levodopa was answered by raising the dose of the drug that started the sequence. The analysis marks that step as the point where the cascade became self-sustaining.
Undoing it in order
Metoclopramide stops first. Levodopa continues until the parkinsonism is reassessed, since drug-induced symptoms can take [weeks to months] to resolve, and then tapers if they have. Gastroparesis gets dietary measures and a named alternative with its own limits.
Where marks go in NU553 Unit 7
Recognizing the sequence as a cascade, and tracing it to its first drug, carries most of the credit. Analyses that treat tremor, then nausea, as separate new problems repeat the error the case depicts. Naming metoclopramide as the cause without explaining central D2 blockade leaves the mechanism criterion thin, and diagnosing Parkinson disease without considering the drug is marked as a missed differential. The loop is the detail that separates strong work from adequate work; missing the final step, the dose increase for levodopa's nausea, loses much of the analysis credit. Plans that stop both drugs at once cost marks, since the order matters for judging recovery. Stopping metoclopramide without addressing gastroparesis leaves the patient worse off. Blaming an individual prescriber, or citing the boxed warning without its year, are smaller faults.
Get a NU553 Unit 7 example written to your instructions
Upload the timeline or medication history your NU553 Unit 7 case provides, along with its directions and rubric; any cascade works, not only this one. In 24-48h, with the first one free, the sample lays the months on one line, tests timing and plausibility, names the step where the cascade closed, and orders the undoing by pharmacology.
NU553 Unit 7 questions, answered
How is a cascade different from an ordinary side effect?
The difference lies in what happens next: an adverse effect turns into a cascade once someone reads it as fresh illness and prescribes for it. The original agent stays, the new one adds its own risks, and sometimes, as here, the second drug's effects prompt more of the first. The analysis earns credit by naming the moment the symptom was treated instead of the cause reviewed.
Should the analysis diagnose the patient with Parkinson disease or not?
It should say the diagnosis is uncertain until the suspected drug has been withdrawn and enough time has passed. Drug-induced parkinsonism often improves after the offending agent stops, though recovery can take months. An analysis that keeps both possibilities open, with a reassessment date, is more defensible than one that settles the question too early in either direction.
What alternatives for gastroparesis can the plan name?
The sample names dietary changes, such as smaller and lower-fat meals, and mentions that other prokinetic options carry their own limits, including availability and interactions. It brackets any agent and amount as composite and routes the choice to the prescriber managing her diabetes. A plan that removes the cause of the cascade still owes the patient a way to manage the original symptom.